Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKAP12 shRNA knockdown refers to the experimental use of short hairpin RNA (shRNA) to suppress the expression of the AKAP12 gene, also known as SSeCKS, AKAP250, or gravin. AKAP12 is a hypoxia-inducible scaffold protein that coordinates signaling complexes involving PKC, Src, and F-actin to regulate cell adhesion and motility. While traditionally viewed as a tumor suppressor in various cancers such as prostate and colon cancer, research in melanoma has identified a pro-oncogenic role for AKAP12. Preclinical studies demonstrate that stable knockdown of AKAP12 in melanoma cell lines significantly reduces their invasive and migratory capabilities in vitro and diminishes tumor growth and metastatic potential in orthotopic and metastatic mouse models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AKAP12 shRNA knockdown.